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ABSTRACT 
Parvovirus is an erythrovirus that infects red cell precursors in individuals with conditions characterised by a high red cell 
turnover like sickle cell anaemia and thalassaemia. Arthritis, vasculitis, carditis, bone marrow failure, and the slapped 
cheek appearance have been associated with Parvovirus B19 infection. Recurrent blood transfusion is a risk factor for the 
B19 serotype of Parvovirus infection, with the P antigen as the mediator for erythroid invasion presenting as transient 
erythroblastopaenia (TEB). Although TEB is self-limiting a few cases may progress to aplastic anaemia. Previous studies 
report seroprevalence rates of between 44 and 71%, but the dearth of data on the seroprevalence of B19 parvovirus strain in  
our region prompted this study.  
Venous blood samples from 239 children aged 1to 15 years of consenting parents and guardians were screened for 
Parvovirus B19 IgG antibodies using the ELISA technique and antibody titer assessed spectrophotometrically. All the 
participants have sickle cell anaemia, but were in the steady state.  
Of this serum samples from 204 (85.4%) participants were positive for IgG antibodies against Parvovirus B19 while 35 
(14.6%) were negative for the IgG antibodies.). The age-group with the highest prevalence is 10-12year group with 
seroprevalence rate of 88.9%.  The overall seroprevalence of Parvovirus B19 antibodies is 85.4 %. 
The seroprevalence of Parvovirus B19 antibodies is high in all socio-economic groups.  Antibody prevalence is higher in the 
non-transfused group suggesting that other factors than transfusion play a role in the spread of the B19 strain of Parvovirus 
B19.   
 
INTRODUCTION 
Parvovirus is of the family parvoviridae, sub family 
parvovirinae; which infect vertebrates as against the 
subfamily densovirinae which infect invertebrates. 
(1,2). Members of Parvovirinae are Amdovirus, 
Bocavirus, Dependovirus, Erythrovirus, 
Partetravirus and Parvovirus(1).   Parvoviruses are 
erythroviruses in view of their ability to replicate 
independently in erythroid and megakaryocyte 
precursors within the bone marrow (2). 
Parvoviruses also infect endothelial and myocardial 
cells(2). While Parvovirus is selectively pathogenic 
to humans, other parvovirus strains are Simian, Pig-
tailed macaque, and Rhesus parvoviruses 
depending on the nature of their hosts (2). 
 
Parvovirus is a non-enveloped isometric virus with 
a diameter of 18-26nm. Crytallography at 3.5 Å 
determined that the parvovirus is an icosahedral 
virus with a polypeptide fold of 2 to 3 major capsid 
proteins, namely VP1, VP2 and VP3 (1,3). The 
genomic particle consists of 60copies of capsid 
protein containing single stranded 
Deoxyribonucleic acid (DNA). Parvovirus genome 
contains 5596 nucleotides, of this 4830 nucleotide 
sequences constitute the encoding sequences; and 
383 flanking sequences on both sides form the 
inverted terminal repetitive sequences(2).  The 
parvovirus B19 also possesses two non-structural 




with polyoma, papilloma and Porcine parvovirus 
(PPV) viruses. Parvovirus’ tropism for erythroid  
progenitor cells is the basis aplastic crisis in persons 
with chronic haemolytic states like sickle cell 
anaemia, hereditary spherocytosis, and 
thalassaemia (5-8).         
 
There are three genotypes of the Parvovirus namely 
B19, LaLi, and V9, but the B19 serotype is the most 
significant having been implicated in acute febrile 
illnesses of childhood like erythema -infectiosum or 
the slapped cheek or fifth disease indicating 
cytopathic effect on endothelial cells. The cellular 
receptor for Parvovirus is the P antigen which is 
present on endothelial and myocardial cells as well 
as precursors of erythroid and megakaryocyte lines.  
 
Cytopathic effect following viral replication within 
infected erythroid precursors results in giant cell 
formation. The virus is spread by droplet infection 
through the naso-pharynx; recurrent blood 
transfusion and immunosuppression are also risk 
factors for infection(8). Foetal loss results from 
foetal red destruction in non-immune pregnant 
women (6-7). Arthritis, vasculitis, myocarditis, liver 
and bone marrow failure are additional clinical 
outcomes of parvovirus infection.  Sickle cell 
individuals are prone to acute splenic sequestration, 
meningo-encephalitis, acute chest and cerebral 




Immunoglobulin M (IgM) antibodies within 1-2 
weeks of infection and Immunoglobulin G (IgG) 
afterwards. Demonstration of viral nuclear 
components by polymerase chain reaction is the 
confirmatory test. But shared homology with some 
viruses like the porcine parvovirus poses a 
challenge in specificity when PCR is the basis of 
diagnosis, therefore real-time PCR is an alternative 
when cross-reactivity is suspected. (1-4N) Bone 
marrow involvement resulting from viraemia 
causes selective destruction of red cell precursors 
with a varying natural history, this ranges from a 
self-limiting transient erythroblastopaenia(TEB) and 
reticulocytopaenia; to a chronic transfusion 
dependent condition characterised by bone marrow 
aplasia(5, 7).   
 
The prevalence of parvovirus antibodies ranges 
from 44 to 71% with an overall prevalence of 53% in 
one study. The team from the children’s hospital of 
Philadelphia reported an IgG prevalence rate of 
70%. The paucity of data on the prevalence of 
Parvovirus B19 infection despite reported cases of 
transfusion dependence in persons in this 
environment prompted this study.         
 
MATERIALS AND METHODS  
Two hundred and thirty nine children aged 1 to 15 
years with sickle cell anaemia who attend the sickle 
cell clinics of Ahmadu Bello University Teaching 
Hospital, Shika Zaria and Barau Dikko Specialist 
Hospital, Kaduna but were in the steady state were 
the participants in this cross-sectional study. 
Consent was obtained from their parents and 
guardians. Their serum samples were screened for 
Parvovirus B19 IgG antibodies using the Enzyme 
Linked Immunosorbent Assay (ELISA) technique 
applying kits manufactured by DRG instruments 
GmbH Frauenbergstrate 18, 35039 Marburg 
Germany.  
 
ELISA Procedure for Anti-Parvovirus IgG Assay 
Quality Control Measures  
The kits are purchased in packs of 96 tests per kit. 
 
Each test kit contains an internal quality control 
pack to validate the efficacy of the assay and results 
according to the manufacturer’s instructions.  
 
Each test kit has 5 wells reserved for blanks and 
controls. 
Low positive was tested in duplicate.  
 
A well was left empty for the substrate blank which 




ELISA method  
About 100µl of conjugate was transferred to each 
well of the micro plate except the blank. Bubbles 
were avoided upon addition. It was then mixed 
well by gently tapping all microplates sides on a flat 
surface. 
The plates were covered with an adhesive seal and 
incubated for 30 minutes at room temperature (30-
32oC). The adhesive seal was removed and 
discarded. Wells were aspirated and washed. 
About 100µl of substrate was added to each well 
including the blank 
After this, it was incubated for 15 minutes at room 
temperature and (30-32oC) and protected from light 
Finally, the reaction was stopped by adding 100µl 
of stop solution in each well including the blank, in 
the same sequence and time intervals as for the 
substrate addition. The plate was gently tapped to 
mix the content of the wells. 
Plates were read according to manufacturer’s 
instructions as follows. 
Dark precipitates of the chromogen to yellow colour 
indicated positive result 
Pale yellow colour indicated negative result. 
The intensity of the reaction was photometrically 
quantitated with a dual filter Enzyme Immuno 
Assay Reader (Sigma diagnostics EIA Multi-well 




Of 239 participants, 120 were males and 119 were 
females. Serum samples from 204 (85.4%) out of 239 
participants were positive for IgG antibodies 
against Parvovirus while 35 (14.6%) were negative 
for the IgG antibodies. Therefore, the 
seroprevalence of Parvovirus antibodies is 85.4 %( 
Table1). The seroprevalence rate by gender is 
99(82.5%) and 105(88.2%) for males and females 
respectively but there is no statistically significant 
difference between the genders (Table2). The age-
group with the highest prevalence is 10-12year 
group with seroprevalence rate of 88.9% (Figure1).  
 
The prevalence rate for Parvovirus antibodies was 
more than 80% in all socio-economic groups and the 
difference in prevalence rates between the groups 
was not statistically significant with the children of 
persons in the higher socio-economic groups having 
highest prevalence rates.  Fifty three (22.2%) were 
previously transfused and 186(77.8%) were not 
transfused. The sero-prevalence by transfusion is 
43/53(81.1%) and 161/186(86.6%) for the transfused 
and non transfused group respectively. There is no 
statistically significant difference between the 


























X2 = 0.001, P< 0.05 at 95% CI 
 
There is a significant association between Immunoglobulin G antibodies to Parvovirus B19 and sickle cell disease. 
 
TABLE 2:  DISTRIBUTION OF PARVOVIRUS B19 IG G AMONG THE DIFFERENT SEXES IN  CHILDREN WITH 
SICKLE CELL DISEASE 
 
 










X2  =  0.210     95% CI 
 
There is no significant association between the presence of IgG to Parvovirus B19 and gender.    P > 0.05     
 
DISCUSSION 
 The majority formed by males in this study is 
contrary to the observations by Konotey Ahulu, 
Aliyu et al, and Mamman et al in which females 
were the majority (10-12).   This may be explained 
by the fact Ahulu, Aliyu and Mamman conducted 
their studies on adult patients and females are more 
likely to comply with clinic attendance than their 
male counterparts. The prevalence rate of 85.4% 
obtained in this study is higher than 70%, 60% and 
56.5% reported by Eis-Hübinger, Dayana and 
Regaya et al. (13-15).  The highest prevalence was in 
the 10 to 12 year age group. This is at variance with 
Ohene Frempong study in which the age 1 to 5 year 
group had the highest prevalence (9).       
The proportion of participants who had a previous 
history of blood transfusion is 22.2% in this study. 
This is less than 60.8% reported by Mamman and 
Durosinmi (12).  This suggests that transfusion 
demand increases with age as complications 
manifest. Paradoxically, the non-transfused group 
had a higher IgG antibody prevalence rate of 86.8% 
than 81.1% observed in the transfused group. 
Therefore, other factors than blood transfusion 
contribute to the transmission of Parvovirus.  











Status No. of children screened Percentage positive 
Negative 35 14.6 
Positive 204 85.4 
Total  239 100% 
Sex No. of samples 
screen 
No. of positive 
samples  
percentage 
Male 120 99 82.5% 
Female 119 105 88.2% 
Total  239 204 85.4% 
76 
FIGURE 1: THE BAR CHART SHOWS THE OVERALL AGE GROUP DISTRIBUTION OF 
B19 IMMUNOGLOBULIN G AMONG CHILDREN WITH SICKLE CELL DISEASE IN SOME PARTS OF 
                                                         Age (years)
  X2 = 0.875, P > 0.05, at 95% Confidence Interval
 
There is no significant association between the presence of Ig G to B19 virus and age group.
 
TABLE 3: THE DISTRIBUTION OF 






X2 = 0.834, P > 0.05, 95% Confidence Interval
 
There is no statistically significant association between the presence of Parvovirus Ig G and socio
 
prevalence rate of 82.4% in the first three years of 
life suggests early infection probably due to droplet 
or aerosol spread (5, 6).  The ubiquitous nature of 
the virus is indicated by near identical prevalence 










Socioeconomic status / 
Fathers’ occupation 















PARVOVIRUS B19 IGG AMONG CHILDREN WITH SICKLE CELL





farmers, cottage craftsmen had a prevalence rate of 
85.6%   on the one hand while children of highly 
skilled professionals and politicians had a 








4-6 yrs 7-9 yrs 10-12 yrs 13-15 yrs
Percentage of positive sample
No. children 
screened 
No.  positive  Percentage positive 
125 107 85.6% 
95 80 84.2% 
19 17 89.5% 










TABLE 4:  DISTRIBUTION OF PARVOVIRUS B19 IG G IN BLOOD TRANSFUSED AND NON 















X2 = 0.324, P > 0.05, 95% Confidence Interval 
There is no significant association between blood transfusion and Parvovirus B19. 
 
Although IgG antibodies were detected by ELISA, 
this is limited by cross-reactivity with other 
parvoviruses, therefore Nucleic Acid Testing and PCR 
are confirmatory tests considering their sensitivity 
and specificity. Neither PCR nor NAT were carried 
out in this study due to logistic and infrastructural 
challenges in our settings in which  
Nigeria is 156th on the Human Development Index 
(16). In conclusion, this calls for studies that will 
assess the prevalence of IgM activity with the aim of 
detecting on-going infection, PCR based sero-
epidemiology that will provide a basis for vaccine 
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Percentage  positive  
Non-transfused 186 161 86.6% 
Transfused  53 43 81.1% 
Total  239 204 85.4% 
78 
